Producer

Fresenius Kabi AG

HQ DE · Hessenwebsite ↗

Fresenius Kabi AG (Bad Homburg, Hessen Germany; subsidiary of Fresenius SE & Co. KGaA; ~€9B revenue) is one of the two largest US suppliers of injectable opioid vials for hospital use. Fresenius Kabi's US pharmaceutical manufacturing includes morphine sulfate injection, fentanyl citrate injection, and hydromorphone HCl injection. US manufacturing sites: Wilson NC (large sterile fill-finish campus) and Grand Island NE. Fresenius Kabi was one of the companies hit by the FDA's heightened enforcement of injectable GMP standards in the 2010s. The Wilson NC facility received FDA Warning Letters for sterile manufacturing deficiencies — a pattern common across the injectable pharmaceutical industry. Fresenius Kabi also produces IV fluids, parenteral nutrition, and biosimilars from its US sites, making it a broad-spectrum hospital injectable supplier whose opioid vial lines compete for the same cleanroom capacity as other critical parenteral products.

5

Inputs supplied

3

Goods downstream

2

Facilities

0

Stories

Where it shows up

Goods downstream

Essential goods that depend on something Fresenius Kabi AG makes, pick one to see the full supply chain.

What else they do

Business segments

The company's full revenue map, where this supply-chain role fits within their broader business.

  • IV Fluids & Parenteral Nutrition

    35%
  • Injectable Pharmaceuticals (Opioids + Oncology)

    40%
  • Biosimilars (Emerging)

    15%
  • Medical Devices (IV Delivery Systems)

    10%

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

  • Did you know2023

    Fresenius Kabi's Wilson, North Carolina sterile manufacturing campus produces four completely distinct drug categories from shared FDA-approved cleanroom infrastructure: (1) IV fluids (normal saline, dextrose — consumed by essentially every hospitalized patient); (2) Injectable opioids (morphine, fentanyl, hydromorphone — for post-surgical pain management; Fresenius Kabi is one of the top two US manufacturers); (3) Oncology injectables (cisplatin, carboplatin, paclitaxel — for cancer chemotherapy); (4) Parenteral nutrition (TPN solutions — for ICU and surgical patients who cannot eat). These four drug categories serve entirely different patient populations and disease states but compete for the same physical cleanroom production hours, the same qualified manufacturing staff, and the same FDA inspection history. During hospital drug shortages — which have become endemic in US hospital pharmacy — a production disruption at Wilson NC simultaneously affects surgical pain management AND cancer chemotherapy AND critically ill ICU nutritional support. The concentration of this clinical product diversity in one major campus is the IV pharmaceutical equivalent of a single plant producing both the engine and the brakes.

    Fresenius Kabi AG
  • Origin2023

    Fresenius SE & Co. KGaA — the German healthcare parent of Fresenius Kabi — traces its founding to 1912 when pharmacist Eduard Fresenius opened a pharmacy in Frankfurt. From a single Frankfurt pharmacy, the Fresenius family enterprise expanded into one of the largest private healthcare companies in the world by building vertically through the healthcare value chain: Fresenius Kabi (IV fluids, injectable drugs, clinical nutrition — what patients receive while hospitalized); Fresenius Medical Care (the world's largest dialysis company — kidney replacement therapy for 350,000+ patients globally); Helios (the largest private hospital network in Germany and Spain); and Vamed (healthcare infrastructure management and rehabilitation). A single corporate lineage from a 1912 Frankfurt pharmacy owns significant portions of European hospital clinical operations, global dialysis infrastructure, and US sterile pharmaceutical manufacturing. The combined Fresenius SE group generates approximately EUR 40+ billion in annual revenue.

    Fresenius Kabi AG